Telix Pharmaceuticals Limited (TLX)
(Delayed Data from NSDQ)
$10.93 USD
+0.88 (8.76%)
Updated Sep 23, 2025 04:00 PM ET
After-Market: $10.92 -0.01 (-0.09%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth F Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
TLX 10.93 +0.88(8.76%)
Will TLX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for TLX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TLX
All You Need to Know About Telix Pharmaceuticals Limited (TLX) Rating Upgrade to Buy
Telix Shares May Gain on the Distribution Deal With Cardinal Health
TLX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Telix Pharmaceuticals Limited (TLX) Upgraded to Buy: What Does It Mean for the Stock?
What Makes Telix Pharmaceuticals Limited (TLX) a Good Fit for 'Trend Investing'
Other News for TLX
UBS Maintains Buy Rating on TLX, Lowers Target Price to $20 | TLX Stock News
Telix Pharmaceuticals price target lowered by $3 at UBS
Is TLX signaling a buying opportunity? Crossed Above 20 Day Moving Average shows up after rising 0.7%
UBS Sticks to Its Buy Rating for Telix Pharmaceuticals (TLPPF)
Telix Pharmaceuticals (TLPPF) Receives a Buy from Morgan Stanley